Context Introduction of novel agents for the management of advanced prostate cancer
provides a range of treatment options with notable benefits for men with metastatic castration …

Comorbidity is an issue of growing importance due to changing demographics and the
increasing number of adults over the age of 65 with cancer. The best approach to the clinical …

Importance We previously showed that detection of androgen receptor splice variant 7 (AR-
V7) in circulating tumor cells (CTCs) from men with castration-resistant prostate cancer …

PURPOSE PROSTVAC, a viral vector–based immunotherapy, prolonged median overall
survival (OS) by 8.5 months versus placebo in metastatic castration-resistant prostate cancer …

Background Enzalutamide is an oral androgen-receptor inhibitor that has been shown to
improve survival in two placebo-controlled phase 3 trials, and is approved for patients with …

Understanding the molecular underpinnings of sensitivity to specific therapies will advance
the goal of precision medicine in prostate cancer (PCa). We identified three patients with …

A potential milestone in personalized nuclear medicine is theranostics of metastatic
castration-resistant prostate cancer (mCRPC) based on molecular imaging using PET/CT …

Metastatic prostate cancer patients present in two ways—with already disseminated disease
at the time of presentation or with disease recurrence after definitive local therapy. Androgen …

Despite a strong preclinical rationale for targeting the insulin-like growth factor (IGF) axis in
cancer, clinical studies of IGF-1 receptor (IGF-1R)-targeted monotherapies have been …

Purpose: CD73 is an adenosine-generating ecto-enzyme that suppresses antitumor
immunity in mouse models of cancer, including prostate cancer. Although high levels of …